开云app官网登录入口网页版-官方正版

#药效学#

11篇内容 | 1022人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1718903, encodeId=f1e41e189033d, content=<a href='/topic/show?id=cf168e59360' target=_blank style='color:#2F92EE;'>#药效学#</a>, objectTitle=Arthritis Rheumatol：Bruton‘s酪氨酸激酶抑制剂Fenebrutinib治疗系统性红斑狼疮的疗效、安全性和药效学效应研究, objectType=article, longId=301207, objectId=11cf30120ed4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11cf30120ed4, replyNumber=0, likeNumber=71, createdTime=2023-02-17, rootId=0, userName=liuhuangbo, userId=b4c132663291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11cf30120ed4, moduleTitle=Arthritis Rheumatol：Bruton‘s酪氨酸激酶抑制剂Fenebrutinib治疗系统性红斑狼疮的疗效、安全性和药效学效应研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=11cf30120ed4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1718902, encodeId=4ba71e1890264, content=<a href='/topic/show?id=cf168e59360' target=_blank style='color:#2F92EE;'>#药效学#</a>, objectTitle=Nat Metab：用于治疗苯丙酮尿症的工程化大肠杆菌菌株的安全性和药效学研究, objectType=article, longId=214950, objectId=b67b2149501e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b67b2149501e, replyNumber=0, likeNumber=78, createdTime=2021-11-21, rootId=0, userName=liuhuangbo, userId=b4c132663291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b67b2149501e, moduleTitle=Nat Metab：用于治疗苯丙酮尿症的工程化大肠杆菌菌株的安全性和药效学研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=b67b2149501e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1718901, encodeId=a7b31e1890106, content=<a href='/topic/show?id=cf168e59360' target=_blank style='color:#2F92EE;'>#药效学#</a>, objectTitle=Clin Cancer Res：预测仑伐替尼（Lenvatinib）在不可切除肝细胞癌中生存获益的药效学生物标志物:来自III期REFLECT研究, objectType=article, longId=214268, objectId=9fbc2142681c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fbc2142681c, replyNumber=0, likeNumber=102, createdTime=2021-10-15, rootId=0, userName=liuhuangbo, userId=b4c132663291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fbc2142681c, moduleTitle=Clin Cancer Res：预测仑伐替尼（Lenvatinib）在不可切除肝细胞癌中生存获益的药效学生物标志物:来自III期REFLECT研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=9fbc2142681c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1718899, encodeId=fd581e18899e1, content=<a href='/topic/show?id=cf168e59360' target=_blank style='color:#2F92EE;'>#药效学#</a>, objectTitle=尼古丁和烟草研究协会（SRNT）年会：I / II期试验阐明了Cytisinicline的多剂量、药代动力学和药效学特征, objectType=article, longId=161124, objectId=282916112457, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=282916112457, replyNumber=0, likeNumber=59, createdTime=2019-11-02, rootId=0, userName=liuhuangbo, userId=b4c132663291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=282916112457, moduleTitle=尼古丁和烟草研究协会（SRNT）年会：I / II期试验阐明了Cytisinicline的多剂量、药代动力学和药效学特征, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=282916112457)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1718900, encodeId=c1d81e18900d9, content=<a href='/topic/show?id=cf168e59360' target=_blank style='color:#2F92EE;'>#药效学#</a>, objectTitle=Clin Chem：偶尔和长期吸食大麻者模拟驾驶对警惕性和事故风险的影响及其药代动力学-药效学关系, objectType=article, longId=175893, objectId=0c821e5893d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c821e5893d6, replyNumber=0, likeNumber=83, createdTime=2019-11-03, rootId=0, userName=liuhuangbo, userId=b4c132663291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c821e5893d6, moduleTitle=Clin Chem：偶尔和长期吸食大麻者模拟驾驶对警惕性和事故风险的影响及其药代动力学-药效学关系, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=0c821e5893d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1718897, encodeId=7bc61e188976c, content=<a href='/topic/show?id=cf168e59360' target=_blank style='color:#2F92EE;'>#药效学#</a>, objectTitle=抗菌药物药代动力学/药效学理论临床应用专家共识, objectType=article, longId=141580, objectId=c267141580eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c267141580eb, replyNumber=0, likeNumber=58, createdTime=2019-04-25, rootId=0, userName=liuhuangbo, userId=b4c132663291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c267141580eb, moduleTitle=抗菌药物药代动力学/药效学理论临床应用专家共识, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=c267141580eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1718898, encodeId=2e1e1e188985c, content=<a href='/topic/show?id=cf168e59360' target=_blank style='color:#2F92EE;'>#药效学#</a>, objectTitle=Diabetic Med：钠-葡萄糖共转运蛋白-2抑制剂依帕列净在2型糖尿病年轻人中的药代动力学和药效学特征, objectType=article, longId=152526, objectId=ad2715252671, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad2715252671, replyNumber=0, likeNumber=102, createdTime=2018-12-18, rootId=0, userName=liuhuangbo, userId=b4c132663291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad2715252671, moduleTitle=Diabetic Med：钠-葡萄糖共转运蛋白-2抑制剂依帕列净在2型糖尿病年轻人中的药代动力学和药效学特征, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ad2715252671)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1718896, encodeId=21101e18896e7, content=<a href='/topic/show?id=cf168e59360' target=_blank style='color:#2F92EE;'>#药效学#</a>, objectTitle=CLIN PHARMACOKINET：1型糖尿病患者速效型胰岛素的药代动力学和药效学特征, objectType=article, longId=100541, objectId=5f5410054125, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f5410054125, replyNumber=0, likeNumber=72, createdTime=2017-06-17, rootId=0, userName=liuhuangbo, userId=b4c132663291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f5410054125, moduleTitle=CLIN PHARMACOKINET：1型糖尿病患者速效型胰岛素的药代动力学和药效学特征, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=5f5410054125)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1718895, encodeId=a0731e18895be, content=<a href='/topic/show?id=cf168e59360' target=_blank style='color:#2F92EE;'>#药效学#</a>, objectTitle=SCI TRANSL MED：ALS的新药效学标志物, objectType=article, longId=94048, objectId=65b3940481f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65b3940481f, replyNumber=0, likeNumber=90, createdTime=2017-11-17, rootId=0, userName=liuhuangbo, userId=b4c132663291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65b3940481f, moduleTitle=SCI TRANSL MED：ALS的新药效学标志物, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=65b3940481f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1718894, encodeId=7efc1e188945a, content=<a href='/topic/show?id=cf168e59360' target=_blank style='color:#2F92EE;'>#药效学#</a>, objectTitle=IJP：生长激素拮抗剂N-末端PEG药效学研究获进展, objectType=article, longId=25741, objectId=79e125e4135, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79e125e4135, replyNumber=0, likeNumber=109, createdTime=2014-09-19, rootId=0, userName=liuhuangbo, userId=b4c132663291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79e125e4135, moduleTitle=IJP：生长激素拮抗剂N-末端PEG药效学研究获进展, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=79e125e4135)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1718893, encodeId=3fde1e1889355, content=<a href='/topic/show?id=cf168e59360' target=_blank style='color:#2F92EE;'>#药效学#</a>, objectTitle=AAC：张云等新型肽类抗生素保护临床耐药菌感染药效学研究获进展, objectType=article, longId=5626, objectId=a5c2562601, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5c2562601, replyNumber=0, likeNumber=122, createdTime=2012-10-04, rootId=0, userName=liuhuangbo, userId=b4c132663291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5c2562601, moduleTitle=AAC：张云等新型肽类抗生素保护临床耐药菌感染药效学研究获进展, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=a5c2562601)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

药效学

2020-05-29

liuhuangbo (审核中...)

前往app查看评论内容

#药效学#

Arthritis Rheumatol：Bruton‘s酪氨酸激酶抑制剂Fenebrutinib治疗系统性红斑狼疮的疗效、安全性和药效学效应研究

2023-02-17

liuhuangbo (审核中...)

前往app查看评论内容

#药效学#

Nat Metab：用于治疗苯丙酮尿症的工程化大肠杆菌菌株的安全性和药效学研究

2021-11-21

liuhuangbo (审核中...)

前往app查看评论内容

#药效学#

Clin Cancer Res：预测仑伐替尼（Lenvatinib）在不可切除肝细胞癌中生存获益的药效学生物标志物:来自III期REFLECT研究

2021-10-15

liuhuangbo (审核中...)

前往app查看评论内容

#药效学#

尼古丁和烟草研究协会（SRNT）年会：I / II期试验阐明了Cytisinicline的多剂量、药代动力学和药效学特征

2019-11-02

liuhuangbo (审核中...)

前往app查看评论内容

#药效学#

Clin Chem：偶尔和长期吸食大麻者模拟驾驶对警惕性和事故风险的影响及其药代动力学-药效学关系

2019-11-03

liuhuangbo (审核中...)

前往app查看评论内容

#药效学#

抗菌药物药代动力学/药效学理论临床应用专家共识

2019-04-25

liuhuangbo (审核中...)

前往app查看评论内容

#药效学#

Diabetic Med：钠-葡萄糖共转运蛋白-2抑制剂依帕列净在2型糖尿病年轻人中的药代动力学和药效学特征

2018-12-18

liuhuangbo (审核中...)

前往app查看评论内容

#药效学#

CLIN PHARMACOKINET：1型糖尿病患者速效型胰岛素的药代动力学和药效学特征

2017-06-17

liuhuangbo (审核中...)

前往app查看评论内容

#药效学#

SCI TRANSL MED：ALS的新药效学标志物

2017-11-17

liuhuangbo (审核中...)

前往app查看评论内容

#药效学#

IJP：生长激素拮抗剂N-末端PEG药效学研究获进展

2014-09-19

liuhuangbo (审核中...)

前往app查看评论内容

#药效学#

AAC：张云等新型肽类抗生素保护临床耐药菌感染药效学研究获进展

2012-10-04

科室
- - 订阅+
  - 更多科室
工具
服务